High-throughput screening identifies proteasome inhibition as promising strategy for treatment of ALK-mutant neuroblastoma
A high-throughput screen identified the proteasome inhibitor ixazomib citrate as a promising therapeutic strategy that selectively targets and inhibits the growth of ALK-mutant neuroblastoma tumors both in vitro and in vivo.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
Neuroblastoma is a cancer that begins in the developing nerve cells of a young child's body, often appearing as a lump in the abdomen or chest. While many children with early-stage versions of this disease recover completely, those with high-risk, advanced forms face a much harder battle. The disease is driven by specific errors in the genetic code of the tumor cells. Two of the most common and dangerous errors involve a gene called MYCN, which acts like a stuck accelerator for cell growth, and a gene called ALK, which can mutate to send constant, uncontrolled signals that tell the cancer to divide and survive. For years, doctors have tried to target these signals directly, but the cancer often finds ways to resist these treatments, leading to relapse. This leaves researchers searching for new ways to attack the tumor, not by blocking the specific broken signal, but by exploiting a different weakness that the cancer cells cannot easily escape.
A team of scientists recently turned to a method called high-throughput screening to find such a weakness. Imagine a laboratory where thousands of different chemical compounds are tested against cancer cells in a matter of days, rather than years. The researchers used this approach to test 198 different drugs, including some already approved for other diseases, against ten different types of neuroblastoma cells. They also compared how these drugs affected neuroblastoma cells versus cells from other aggressive brain tumors, looking for a drug that would specifically hurt the neuroblastoma without harming the others as much. The goal was to find a pattern: a drug that worked best on the specific genetic errors found in the most dangerous cases of the disease.
The screening process revealed a surprising result. While the researchers expected to find drugs that blocked the ALK signal directly, the data pointed toward a different mechanism entirely. The analysis showed that the neuroblastoma cells carrying the ALK mutation were uniquely vulnerable to a class of drugs known as proteasome inhibitors. A proteasome is a tiny machine inside every cell that acts as a recycling center, breaking down old or damaged proteins so the cell can reuse the materials. When this machine is blocked, the cell becomes clogged with toxic protein waste, eventually leading to its death. Among the drugs tested, a specific compound called ixazomib citrate stood out. It showed a strong ability to kill only the neuroblastoma cells with the ALK mutation, while leaving the cells without that mutation largely unharmed.
To confirm this finding, the researchers moved from the test tubes to living models. They treated neuroblastoma cells in the lab with ixazomib citrate and watched what happened. The cells carrying the ALK mutation began to die rapidly, showing clear signs of self-destruction, a process called apoptosis. They also showed signs of severe damage to their DNA, which further ensured they could not survive. In contrast, the cells without the mutation remained mostly healthy. The researchers then took this a step further by growing tumors made from these ALK-mutant cells under the skin of mice. When they gave the mice ixazomib citrate, the tumors stopped growing and began to shrink. The treatment was just as effective at controlling the tumor growth as a drug designed to directly block the ALK signal, but it worked through a completely different path.
The study suggests that the ALK mutation might make these cancer cells rely heavily on their protein recycling machines to survive. When the researchers blocked this machine with ixazomib citrate, the cells could not handle the buildup of waste and collapsed. This is significant because it offers a new strategy for patients whose tumors have become resistant to standard treatments. The researchers noted that while direct ALK inhibitors have shown limited success in the past, this approach of targeting the cell's internal cleanup system could be a powerful alternative. The findings are not yet a cure, and the researchers caution that more work is needed to understand exactly why the mutation makes the cells so sensitive to this specific drug. However, the results provide strong evidence that ixazomib citrate, a drug already approved for a different type of blood cancer, could be repurposed to treat a specific, difficult form of neuroblastoma, offering a new hope for children who have few other options.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.